Sujal M. Patel Purchases 53,300 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel acquired 53,300 shares of Nautilus Biotechnology stock in a transaction on Wednesday, March 19th. The stock was purchased at an average cost of $0.99 per share, with a total value of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at approximately $10,016,610.12. This trade represents a 0.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Nautilus Biotechnology Stock Down 1.0 %

Shares of NASDAQ:NAUT opened at $0.99 on Friday. The business’s 50 day moving average is $1.54 and its 200 day moving average is $2.11. Nautilus Biotechnology, Inc. has a 12-month low of $0.93 and a 12-month high of $3.09. The stock has a market cap of $124.89 million, a price-to-earnings ratio of -1.77 and a beta of 1.25.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Nautilus Biotechnology by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company’s stock valued at $1,920,000 after purchasing an additional 7,000 shares in the last quarter. Palumbo Wealth Management LLC lifted its position in shares of Nautilus Biotechnology by 45.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after buying an additional 8,888 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after buying an additional 9,904 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after acquiring an additional 13,363 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Nautilus Biotechnology during the fourth quarter worth $28,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NAUT. The Goldman Sachs Group cut Nautilus Biotechnology from a “neutral” rating to a “sell” rating and cut their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th. Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.